Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine: an immunosuppressive panacea?

J G Copeland, R W Emery, M M Levinson

    The Journal of Thoracic and Cardiovascular Surgery
    |January 1, 1986
    PubMed
    Summary

    Cyclosporine heart transplant patients experienced shorter hospital stays and reduced costs, but showed increased blood pressure and potential kidney damage. Careful dosing is recommended to mitigate these risks.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Progress on the total artificial heart.

    Surgical technology international·2015
    Same author

    Penicillin in dentistry.

    Tufts dental outlook·2010
    Same author

    University of Arizona, Cardiac Transplantation: changing patterns in selection and outcomes.

    Clinical transplants·2002
    Same author

    Altruism versus reality: an academic medical center's role in device development.

    Artificial organs·2002
    Same author

    Severe, refractory hypotension during anesthesia in a patient on chronic clomipramine therapy.

    Anesthesiology·2001
    Same author

    Advanced medical therapy does not render heart transplantation obsolete for ambulatory end-stage heart failure patients: a debate.

    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2001

    Area of Science:

    • Nephrology
    • Cardiology
    • Transplantation Immunology

    Background:

    • Heart transplantation is a critical treatment for end-stage heart failure.
    • Immunosuppression is vital to prevent organ rejection post-transplant.
    • Cyclosporine emerged as a novel immunosuppressive agent with a distinct side-effect profile.

    Purpose of the Study:

    • To compare the efficacy and safety of conventional immunosuppression versus cyclosporine in heart transplant recipients.
    • To evaluate differences in survival, rejection episodes, infections, and complications.
    • To assess the economic impact and renal toxicity associated with cyclosporine therapy.

    Main Methods:

    • Retrospective analysis of 62 heart transplants performed between 1979 and 1985.
    • Comparison of two groups: conventional immunosuppression and cyclosporine.

    Related Experiment Videos

  • Evaluation of actuarial survival, rejection rates, infection rates, complications, hospital stay, rehospitalizations, and costs.

    • Main Results:

    • No significant differences in survival, rejection, or infection rates between the two groups.
    • Cyclosporine group showed increased blood urea nitrogen, serum creatinine, and diastolic blood pressure.
    • Cyclosporine group had halved hospital stays and fewer rehospitalizations, leading to decreased overall costs despite higher pharmaceutical expenses.

    Conclusions:

    • Cyclosporine is an effective immunosuppressant but poses risks of renal toxicity.
    • Minimal differences in survival and rejection suggest potential for dose modification.
    • Reducing or adjusting cyclosporine dosage may prevent irreversible kidney damage without compromising transplant outcomes.